# OnCo record actuate-1801 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/actuate-1801/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "actuate-1801", "NCT03678883" ;
  schema:name "Actuate 1801 Part 3B (elraglusib)"@en ;
  schema:alternateName "actuate-1801"@en, "Actuate 1801"@en, "9-ING-41 in Patients With Advanced Cancers"@en ;
  schema:description "A randomised phase 2 found that adding the GSK-3 inhibitor elraglusib to standard chemotherapy lengthened survival in metastatic pancreatic cancer; a phase 3 is needed to confirm it."@en ;
  schema:url <https://onco.cc/trials/actuate-1801/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03678883>, <https://doi.org/10.1038/s41591-026-04327-4>, <https://doi.org/10.1038/s41591-026-04327-4> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2019-01-04" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/elraglusib/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/actuate-therapeutics/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mahalingam-nat-med/> .